StockData
Hemab Therapeutics Holdings, Inc. logo

Hemab Therapeutics Holdings, Inc. (COAG) stock

COAGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$39.06+0.01 (+0.01%)

Close on Nov 17, 2026Market cap $1.82BP/E –Yield –

Hemab Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$24.64M+91.4%
Q2 FY2026Jun 30, 2026$20.34M+44.2%
Q1 FY2026Mar 31, 2026$19.46M–
Q3 FY2025Sep 30, 2025$14.56M–
Q2 FY2025Jun 30, 2025$12.87M–
Q1 FY2025Mar 31, 2025$14.10M–

More Hemab Therapeutics figures

See a number that looks wrong?